GCP
EGRX

GSA Capital Partners’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

GSA Capital Partners’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-83,137
Closed -$435K – 2052
2023
Q4 		$435K Buy
83,137
+57,691
+227% +$570K 0.04% 889
2023
Q3 		$401K Sell
25,446
-11,136
-30% -$200K 0.03% 926
2023
Q2 		$711K Buy
36,582
+22,358
+157% +$530K 0.07% 520
2023
Q1 		$404K Buy
+14,224
New +$422K 0.04% 850
2022
Q4 		– Sell
-23,137
Closed -$611K – 1982
2022
Q3 		$611K Buy
23,137
+6,081
+36% +$223K 0.08% 427
2022
Q2 		$758K Buy
17,056
+636
+4% +$29.2K 0.11% 268
2022
Q1 		$813K Buy
16,420
+11,657
+245% +$559K 0.11% 265
2021
Q4 		$243K Buy
+4,763
New +$247K 0.03% 1082
2020
Q2 		– Sell
-6,142
Closed -$283K – 1206
2020
Q1 		$283K Sell
6,142
-4,225
-41% -$212K 0.07% 525
2019
Q4 		$623K Sell
10,367
-1,475
-12% -$88K 0.07% 499
2019
Q3 		$670K Sell
11,842
-7,164
-38% -$403K 0.09% 360
2019
Q2 		$1.06M Sell
19,006
-4,046
-18% -$211K 0.12% 209
2019
Q1 		$1.16M Sell
23,052
-9,348
-29% -$416K 0.12% 227
2018
Q4 		$1.3M Buy
32,400
+8,500
+36% +$438K 0.15% 131
2018
Q3 		$1.66M Buy
23,900
+18,600
+351% +$1.41M 0.09% 347
2018
Q2 		$401K Sell
5,300
-2,500
-32% -$157K 0.02% 1262
2018
Q1 		$411K Sell
7,800
-32,000
-80% -$1.86M 0.02% 1161
2017
Q4 		$2.13M Buy
39,800
+23,900
+150% +$1.33M 0.13% 212
2017
Q3 		$948K Sell
15,900
-12,600
-44% -$762K 0.06% 562
2017
Q2 		$2.25M Sell
28,500
-3,500
-11% -$286K 0.15% 125
2017
Q1 		$2.65M Buy
+32,000
New +$2.38M 0.14% 147
2016
Q2 		– Sell
-32,296
Closed -$1.31M – 1960
2016
Q1 		$1.31M Buy
32,296
+24,539
+316% +$1.56M 0.08% 403
2015
Q4 		$688K Sell
7,757
-2,388
-24% -$189K 0.03% 956
2015
Q3 		$751K Buy
+10,145
New +$844K 0.04% 862
2015
Q2 		– Sell
-21,500
Closed -$901K – 2227
2015
Q1 		$901K Buy
+21,500
New +$610K 0.04% 949

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

GSA Capital Partners's EGRX Position: Q1 2024 in Review

GSA Capital Partners sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2024, closing a stake of 83,137 shares — an estimated $435K sold.

GSA Capital Partners first reported a position in EGRX in Q1 2015 and held it in 25 quarters. The position peaked at $2.65M in Q1 2017. 91 funds tracked by Wall St. Rank hold EGRX as of Q1 2024.

  • GSA Capital Partners reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • GSA Capital Partners sold 83,137 Eagle Pharmaceuticals, Inc. shares in Q1 2024, an estimated $435K.
  • GSA Capital Partners first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 25 quarters.
  • GSA Capital Partners's Eagle Pharmaceuticals, Inc. position peaked at $2.65M in Q1 2017.
  • 91 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2024.

Based on GSA Capital Partners's 13F filing for Q1 2024, filed 3 May 2024.